Secretome Therapy (Cell-Free Conditioned Media) for Regenerative Medicine — Regenerative Therapies
Complete cell-free bioactive secretome containing growth factors, cytokines, and extracellular vesicles from cultured stem cells.
Overview
The secretome encompasses the complete set of bioactive molecules secreted by cells into their extracellular environment - growth factors (VEGF, HGF, EGF, PDGF, FGF, IGF), cytokines (IL-10, TGF-beta), chemokines, exosomes/extracellular vesicles, and matrix metalloproteinases. Secretome therapy uses conditioned media from cultured stem cells as a cell-free therapeutic. The rationale is that much of the therapeutic benefit of stem cell therapy comes from paracrine factors rather than direct cell engraftment. Advantages over cell therapy: eliminable tumorigenicity risk, easier standardization, potential for off-the-shelf lyophilized products, no need for immunosuppression, and simpler regulatory pathway. PRP represents the most widely used form of autologous secretome therapy.
Indications
- Post-surgical wound healing acceleration
- Skin rejuvenation and anti-aging (dermatology)
- Hair restoration and androgenic alopecia
- Osteoarthritis (joint injection)
- Chronic non-healing wounds
- Burn wound management
- Peripheral nerve regeneration
- Tendon and ligament repair
Mechanism of Action
MSCs or other source cells cultured under specific conditions (serum-free, hypoxic, or with inflammatory priming). Conditioned media collected after 48-72h
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| MSC Conditioned Media | 1-5 mL conditioned media | Series of 3-6 treatments, 2-4 weeks apart | Intradermal injection for skin rejuvenation (investigational) |
| MSC Secretome / PRP | 2-8 mL | Single injection, may repeat at 3-6 months | Intra-articular injection for osteoarthritis |
| Lyophilized Secretome | Topical application | 2-3 times weekly until wound closure | Applied to chronic wounds after debridement |
Evidence Grade
GRADE C
Safety & Contraindications
- Not FDA-approved as a standalone therapeutic
- No standardized manufacturing or characterization protocols
- Batch-to-batch variability in growth factor concentrations
- Autologous preparations vary by patient age, health, and cellular source
- Risk of contamination during manufacturing without GMP controls
- Pro-tumorigenic potential: growth factors (VEGF, EGF, PDGF) may promote cancer growth
- Stability concerns: proteins degrade quickly without proper storage
- PRP (most common form) has variable evidence across indications
- Distinction between secretome, conditioned media, PRP, and exosomes often blurred